Nifedipin T Retard Al (Nifedipine)

Nifedipine blocks L‑type calcium channels on vascular smooth‑muscle cells, preventing calcium entry that triggers contraction. This causes arterial dilation, lowers peripheral resistance, and reduces blood pressure. In the heart’s vessels, the dilation improves blood flow, decreasing the workload and oxygen demand of the myocardium.

The specific dose and dosing schedule for Nifedipin T Retard Al are determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for nifedipine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Nifedipine belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes arterial vasodilation. Compared with ACE inhibitors or beta‑blockers, it has a rapid onset of vasodilatory effect but may cause reflex tachycardia and peripheral edema more frequently. Choice of therapy depends on patient profile and comorbidities.

Store Nifedipin T Retard Al at room temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Nifedipin T Retard Al is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed, unless the prescribing information specifically allows a different method of administration.

Serious risks include severe hypotension, myocardial infarction, life‑threatening arrhythmias, and rare allergic reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience fainting, chest pain, irregular heartbeat, or signs of a severe skin reaction.

Patients with known hypersensitivity to nifedipine or other dihydropyridine calcium‑channel blockers should not use the product. It is also contraindicated in individuals with severe aortic stenosis, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors without close medical supervision.